Home › Funds › PLATINUM INVESTMENT MANAGEMENT LTD › CCCC
PLATINUM INVESTMENT MANAGEMENT LTD position in CCCC
C4 THERAPEUTICS INC · Health Care
PLATINUM INVESTMENT MANAGEMENT LTD reported holding 577,534 shares of CCCC (C4 THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$1.9M, representing 0.98% of its reported portfolio and ranking #37 among its reported holdings. PLATINUM INVESTMENT MANAGEMENT LTD has disclosed CCCC holdings in 3 of the last 3 reported quarters, going back to Q1 2026.
Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR
How PLATINUM INVESTMENT MANAGEMENT LTD's CCCC position evolved
PLATINUM INVESTMENT MANAGEMENT LTD first disclosed a stake in CCCC in Q1 2026 at 384,766 shares (US$1.0M). The position peaked in Q3 2026 at 577,534 shares, worth US$1.9M. Across 3 filings, PLATINUM INVESTMENT MANAGEMENT LTD increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 577,534 shares valued at US$1.9M — an increase of 192,768 shares quarter over quarter.. Notable position changes include a 50% increase in Q3 2026 (shares fell 17% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2026 | 384.77K | $1.01M | New |
| Q2 2026 | 384.77K | $1.80M | Hold |
| Q3 2026 | 577.53K | $1.92M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About CCCC and 13F data
CCCC (C4 THERAPEUTICS INC) is a Health Care company. 46 other funds we track also report a position in CCCC — the largest reported positions include RA CAPITAL MANAGEMENT, L.P. (US$37.4M), Lynx1 Capital Management LP (US$34.2M), Bain Capital Life Sciences Investors, LLC (US$23.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding CCCC
- RA CAPITAL MANAGEMENT, L.P. 8.00M sh · $37.36M · Q2 2026
- Lynx1 Capital Management LP 7.33M sh · $34.22M · Q2 2026
- Bain Capital Life Sciences Investors, LLC 7.17M sh · $23.88M · Q3 2026
- Soleus Capital Management, L.P. 3.38M sh · $15.78M · Q2 2026
- SILVERARC CAPITAL MANAGEMENT, LLC 3.45M sh · $11.50M · Q3 2026
- Ikarian Capital, LLC 2.43M sh · $11.36M · Q2 2026
- STEMPOINT CAPITAL LP 3.29M sh · $10.97M · Q3 2026
- HighVista Strategies LLC 873.28K sh · $2.91M · Q3 2026
- Squadron Capital Management LLC 400.00K sh · $1.87M · Q2 2026
- Seven Fleet Capital Management LP 381.17K sh · $1.78M · Q2 2026
More on PLATINUM INVESTMENT MANAGEMENT LTD
FAQ
How long has PLATINUM INVESTMENT MANAGEMENT LTD held CCCC?
PLATINUM INVESTMENT MANAGEMENT LTD has disclosed CCCC holdings in 3 of the last 3 reported quarters, going back to Q1 2026.
What is PLATINUM INVESTMENT MANAGEMENT LTD's current position in CCCC?
As of Q3 2026, PLATINUM INVESTMENT MANAGEMENT LTD holds 577.53K shares of CCCC (C4 THERAPEUTICS INC), valued at $1.92M, representing 0.98% of its reported portfolio and ranking #37.
Has PLATINUM INVESTMENT MANAGEMENT LTD been buying or selling CCCC?
In the latest 13F filing (Q3 2026), PLATINUM INVESTMENT MANAGEMENT LTD increased its position in CCCC. The position peaked in Q3 2026 at 577.53K shares.
Which other funds hold CCCC?
Other major institutional holders of CCCC include RA CAPITAL MANAGEMENT, L.P., Lynx1 Capital Management LP, Bain Capital Life Sciences Investors, LLC, among 46 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.